JYANT Technologies, Inc.
JYANT Technologies, Inc. is an early stage product development company founded in 2010, focused on developing and delivering disruptive therapies and diagnostics for unmet medical needs in oncology and inflammatory diseases. The company leverages its strong intellectual property and patented technologies, including anti-chemokine and anti-chemokine receptor antibodies, nanotechnology, and novel manufacturing methods, to provide solutions for diagnosis and treatment of cancers and inflammatory conditions. JYANT aims to bring medical products to market faster through its innovative platform and strategic partnerships.
Industries
Nr. of Employees
small (1-50)
JYANT Technologies, Inc.
Products
Antibody therapeutics targeting chemokines/chemokine receptors
Therapeutic antibody candidates directed at chemokines and chemokine receptors for oncology and inflammatory disease indications; development includes antibodies for CXCL9, CXCL10, CXCL11, CXCL13, CCL25 and receptors such as CXCR3, CXCR5, CCR9.
Fusion polypeptide (chemokine-immunoglobulin / chemokine-polymer) antagonists
Chemokine-immunoglobulin and chemokine-polymer/PEG fusion polypeptides designed to block chemokine receptors with high affinity and extended serum half-lives for treatment of receptor-mediated disorders.
Nanoformulated therapeutic and diagnostic particle platforms
Nano- and micro-particle platforms produced by planetary ball milling and controlled formulation to encapsulate therapeutics, biologics, diagnostics, and insoluble molecules for mucosal or parenteral delivery.
Antibody therapeutics targeting chemokines/chemokine receptors
Therapeutic antibody candidates directed at chemokines and chemokine receptors for oncology and inflammatory disease indications; development includes antibodies for CXCL9, CXCL10, CXCL11, CXCL13, CCL25 and receptors such as CXCR3, CXCR5, CCR9.
Fusion polypeptide (chemokine-immunoglobulin / chemokine-polymer) antagonists
Chemokine-immunoglobulin and chemokine-polymer/PEG fusion polypeptides designed to block chemokine receptors with high affinity and extended serum half-lives for treatment of receptor-mediated disorders.
Nanoformulated therapeutic and diagnostic particle platforms
Nano- and micro-particle platforms produced by planetary ball milling and controlled formulation to encapsulate therapeutics, biologics, diagnostics, and insoluble molecules for mucosal or parenteral delivery.
Services
Strategic partnership development
Collaboration formation with academic and industry partners to support discovery, development, and delivery of therapeutic and diagnostic candidates.
Strategic partnership development
Collaboration formation with academic and industry partners to support discovery, development, and delivery of therapeutic and diagnostic candidates.
Expertise Areas
- Chemokine-targeted therapeutics
- Fusion protein therapeutic development
- Nanoparticle formulation and nano-compounding
- Biomarker-based diagnostics
Key Technologies
- Monoclonal antibody therapeutics
- Chemokine and chemokine receptor targeting
- Immunoglobulin-fusion polypeptides
- PEGylation and polymer conjugation